Eplerenone in patients with myocardial infarction and “mid‐range” ejection fraction: An analysis from the EPHESUS trial

BACKGROUND: Trials using mineralocorticoid receptor antagonists (MRAs) in myocardial infraction (MI) without heart failure (HF) or systolic impairment have been underpowered to assess morbidity‐mortality benefit. In EPHESUS 6632 patients were included, of whom 11% had an ejection fraction (EF) of 40...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, João Pedro, Rossello, Xavier, Pitt, Bertram, Rossignol, Patrick, Zannad, Faiez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2019
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6837025/
https://www.ncbi.nlm.nih.gov/pubmed/31482613
http://dx.doi.org/10.1002/clc.23261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6837025/
https://www.ncbi.nlm.nih.gov/pubmed/31482613
http://dx.doi.org/10.1002/clc.23261

Ejemplares similares